Novo Nordisk Announces New CagriSema Study Data
Novo Nordisk announced new study data on low-dose CagriSema in people with overweight and obesity.
Related stories
Transportadora de Gas del Sur Reports Quarterly Results
The company reported results for the quarter ended September 30; no financial figures are provided.
M impact | EQUITY | Oct 30, 2026, 12:25 AM UTC
Amazon shares fall as AI spending accelerates cash outflow
Amazon's cloud business is performing well, but AI investment is accelerating cash outflow.
M impact | EQUITY | Oct 30, 2026, 12:24 AM UTC
Bambusa Offers All Shares
Bambusa is offering all of its shares.
M impact | EQUITY | Oct 30, 2026, 12:23 AM UTC
Bambusa Upsizes IPO to 10.6 Million Shares at $16 Per Share
M impact | EQUITY | Oct 30, 2026, 12:23 AM UTC
Kolmar Korea to Hold Q3 Results Call for Analysts on Nov. 6
Kolmar Korea plans to present its third-quarter results on an analyst conference call at 10:30 a.m. on Nov. 6, 2026.
M impact | EQUITY | Oct 30, 2026, 12:21 AM UTC
Kolmar Korea to Host Q3 Results Call for Analysts
M impact | EQUITY | Oct 30, 2026, 12:21 AM UTC